Boehringer Ingelheim India Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Boehringer Ingelheim India Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $772.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Boehringer Ingelheim India Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $772.3K Trade | TransData Nexus

Boehringer Ingelheim India Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $772.3K Total Trade · DGFT Verified

Boehringer Ingelheim India Private Limited is an Indian pharmaceutical exporter with a total trade value of $772.3K across 2 products in 2 therapeutic categories. Based on 42 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Empagliflozin ($681.8K), Linagliptin ($90.5K), .

Boehringer Ingelheim India Private Limited — Export Portfolio & Destination Treemap

Boehringer Ingelheim India Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Boehringer Ingelheim India Private Limited? — Company Overview & Market Position

Boehringer Ingelheim India Private Limited, incorporated on December 11, 2003, is a private unlisted company based in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2003PTC143499. Its authorized and paid-up capital stands at ₹6.47 crore (approximately $772,000 USD). The registered office is located at Unit No. 202, 2nd Floor, Godrej 2, Pirojsha Nagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra 400079, India.

As a subsidiary of the German multinational pharmaceutical company Boehringer Ingelheim, the Indian entity focuses on the manufacturing and export of finished pharmaceutical formulations. The parent company, Boehringer Ingelheim, was founded in 1885 and is one of the world's largest privately held pharmaceutical companies.

What Does Boehringer Ingelheim India Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Empagliflozin$681.8K 2Linagliptin

Product Portfolio — Top 2 by Export Value

Boehringer Ingelheim India Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Empagliflozin	Diabetes & Endocrine	$681.8K	28	10.2%	2
2	Linagliptin	Advanced Diabetes Medications	$90.5K	14	2.3%	4

Boehringer Ingelheim India Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $772.3K. The top category is Diabetes & Endocrine (88.3% of portfolio), followed by Advanced Diabetes Medications (11.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Boehringer Ingelheim India Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Boehringer Ingelheim India Private Limited operates manufacturing facilities in India, specializing in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company exports two products across two therapeutic categories, with a total export value of $772,000 USD and 42 shipments. The top two products exported are Empagliflozin, with an export value of $682,000 USD and a market share of 10.2%, and Linagliptin, with an export value of $90,000 USD and a market share of 2.3%. The primary therapeutic category is Diabetes & Endocrine, accounting for 88.3% of exports, followed by Advanced Diabetes Medications at 11.7%.

3Key Leadership

The leadership team of Boehringer Ingelheim India Private Limited includes:

Sandipkumar Rameshchandra Agrawal: Director since October 11, 2017.

Sanjay Srivastava: Director since November 21, 2022.

Shriya Mandar Oak: Director since May 23, 2024.

The Managing Director and Chief Financial Officer positions are not specified in the available sources. For detailed information on the executive team, it is recommended to contact the company directly or consult official corporate filings.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Boehringer Ingelheim India Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Boehringer Ingelheim India Private Limited's export activities are primarily focused on the United States, European Union, United Kingdom, Australia, and Japan. The company exports finished pharmaceutical formulations, including Empagliflozin and Linagliptin, to these markets. Specific regulatory filings, approvals, and market access statuses for each country are not detailed in the available sources. For comprehensive information, it is advisable to consult the respective regulatory agencies or the company's official communications.

2Emerging Markets

The company's export data does not specify activities in Africa, Latin America, or Southeast Asia. However, Boehringer Ingelheim India Private Limited has a partnership with Alivira Animal Health Limited, a fully owned subsidiary of Viyash Scientific Limited, for the distribution and promotion of its companion animal products portfolio in India. This partnership, announced on January 23, 2026, aims to leverage growth opportunities in the Indian pet healthcare market.

3Geographic Strategy

Boehringer Ingelheim India Private Limited's export portfolio is highly concentrated, with the top two products—Empagliflozin and Linagliptin—accounting for 100% of exports. This indicates a lack of diversification in the product range, which could pose risks if market dynamics change. The company's strategic direction appears to focus on the diabetes and endocrine therapeutic areas, aligning with global trends in the pharmaceutical industry. To mitigate concentration risks, exploring additional therapeutic categories and expanding the product portfolio could be beneficial.

Boehringer Ingelheim India Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Boehringer Ingelheim India Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. For accurate and up-to-date information, it is recommended to consult the FDA's official database or contact the company directly.

2WHO & EU GMP

The available sources do not provide information on Boehringer Ingelheim India Private Limited's World Health Organization (WHO) prequalification status, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. For detailed certifications, it is advisable to refer to the company's official communications or contact the relevant regulatory bodies.

3CDSCO & Indian Regulatory

Specific details regarding Boehringer Ingelheim India Private Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not available in the provided sources. For comprehensive information, consulting the CDSCO or the company's official communications is recommended.

Boehringer Ingelheim India Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the diabetes and endocrine therapeutic categories, Boehringer Ingelheim India Private Limited faces competition from several global and local pharmaceutical companies. While specific market share data is not available, companies such as Novo Nordisk, Sanofi, and Merck are prominent players in these segments. A detailed head-to-head analysis would require access to proprietary market research data.

2Key Differentiators

Boehringer Ingelheim India Private Limited's focus on the diabetes and endocrine therapeutic areas positions it to address the growing global prevalence of these conditions. The partnership with Alivira Animal Health Limited enhances its presence in the Indian pet healthcare market, diversifying its portfolio beyond human pharmaceuticals. These strategic initiatives may provide a competitive edge in the evolving healthcare landscape.

3Strategic Position

The company's current strategic direction emphasizes the diabetes and endocrine therapeutic areas, with a recent expansion into the animal health sector through the partnership with Alivira Animal Health Limited. This diversification strategy aims to leverage growth opportunities in the Indian pet healthcare market. Future outlooks would depend on the successful execution of these strategies and the company's ability to adapt to changing market dynamics.

Buyer Due Diligence Brief — Evaluating Boehringer Ingelheim India Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Boehringer Ingelheim India Private Limited has demonstrated a consistent export volume, with a total export value of $772,000 USD and 42 shipments. The concentration of exports in two products suggests a focused approach, which could be advantageous in maintaining quality and supply chain efficiency. However, the lack of product diversification may pose risks if market conditions change. Reliability indicators such as on-time delivery and compliance with international quality standards are not specified in the available sources.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practices. This information can be obtained from the WHO's official website or the company's communications.

Frequently Asked Questions — Boehringer Ingelheim India Private Limited

How many pharmaceutical products does Boehringer Ingelheim India Private Limited export from India?

Boehringer Ingelheim India Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Empagliflozin ($681.8K), Linagliptin ($90.5K). Total export value is $772.3K.

What is Boehringer Ingelheim India Private Limited's total pharmaceutical export value?

Boehringer Ingelheim India Private Limited's total pharmaceutical export value is $772.3K, based on 42 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Boehringer Ingelheim India Private Limited cover?

Boehringer Ingelheim India Private Limited exports across 2 therapeutic categories. The largest are Diabetes & Endocrine (88.3%, 1 products), Advanced Diabetes Medications (11.7%, 1 products).

Get Full Boehringer Ingelheim India Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.